

13. Lambert-Zechovsky N, Bingen E, Denamur E, et al. Molecular analysis provides evidence for endogenous origin of bacteremia and meningitis to *Enterobacter cloacae* in an infant. *Clin Infect Dis* 1992;15:30-32.
14. Falkiner FR. *Enterobacter* in hospital. *J Hosp Infect* 1992;20:137-140.
15. Burman LG, Bergland B, Huovinen P, Tullus K. Effect of ampicillin versus cefuroxime on the emergence of β -lactam resistance in faecal *Enterobacter cloacae* isolates from neonates. *J Antimicrob Chemother* 1993;31:111-116.
16. Chow JW, Fine MJ, Shales DM, et al. *Enterobacter* bacteremia: clinical features and emergence of antibiotic resistance during therapy. *Ann Intern Med* 1991;115:585-590.
17. Sanders CC. New β -lactams: new problems for the internist. *Ann Intern Med* 1991;115:650-651.
18. Springer C, Eyal F, Michel J. Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. *J Pediatr* 1982;100:647-650.
19. Rhodes KH, Henry NK. Antibiotic therapy of severe infections in infants and children. *Mayo Clin Proc* 1992;67:59-68.
20. Schaad UB. Use of quinolones in pediatrics. *Eur J Clin Microbiol Infect Dis* 1991;10:355-360.
21. Aujard Y, Bingen E. Quinolones, from a compassionate to a rational use in children. *Curr Opin Pediatr* 1992;4:291-294.
22. Gaston MA, Creech Morris JA, Pitt TL. Serotypes and biochemical profiles of British hospital strains of *Enterobacter cloacae* in relation to site of infection and antibiotic susceptibility. *J Hosp Infect* 1987;10:17-27.
23. Poilane I, Craud P, Lachassine E, et al. *Enterobacter cloacae* cross-colonization in neonates demonstrated by ribotyping. *Eur J Clin Microbiol Infect Dis* 1993;12:820-826.
24. Van Belkum A, Melchers W, de Pauw B, Scherer S, Quint W, Meis J. Genotypic characterization of sequential *Candida albicans* isolates from fluconazole-treated neutropenic patients. *J Infect Dis* 1994;169:1062-1070.
25. Van Belkum A, Quint WGV, de Pauw BE, Melchers WJG, Meis JF. Typing of *Aspergillus* species and *Aspergillus fumigatus* isolates by interrepeat polymerase chain reaction. *J Clin Microbiol* 1993;31:2502-2505.
26. Verweij PE, Geven WB, Van Belkum A, Meis JF. Cross-infection with *Pseudomonas aeruginosa* in a neonatal intensive care unit characterized by polymerase chain reaction fingerprinting. *Pediatr Infect Dis* 1993;12:1027-1029.

First AIDS-Related Settlement for ADA After Refusal to Treat

by Gina Pugliese, RN, MS
Medical News Editor

The U.S. Justice Department recently announce that a Houston dental office will pay \$100,000 in damages and penalties for refusing to treat a patient with AIDS. The settlement is the first AIDS-related agreement with a dental service under the Americans with Disabilities Act (ADA). The dental center

refused to continue orthodontic treatment of a patient after he disclosed in a questionnaire that he was HIV positive. The suit was tiled under title III of the ADA, which prohibits discrimination against persons with disabilities in places of public accommodation, such as medical offices.

The Justice Department noted that the CDC and the American Dental Association have issued policy guidelines stating that there is no

medical justification for excluding those with HIV from dental care solely on the basis of their HIV status and recommend the use of universal precautions to prevent the transmission of bloodborne diseases, including AIDS.

FROM: U.S. versus Castle, DC S Texas, No. H-93-3140, filed October 4, 1993; settlement reached September 22, 1994.